Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium lactis BS01
- Development stage
- Unknown
- Lead developer
- Probiotical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis BS01 is a specific probiotic strain of the species *Bifidobacterium animalis* subsp. *lactis*, identified by the deposit number LMG P-21384. Developed by Probiotical S.p.A., this strain is utilized in clinical research for its potential to colonize the human gastrointestinal tract and modulate host physiological processes. Studies have investigated its efficacy in improving cognitive function, aiding weight loss, and influencing immune responses through the polarization of monocyte and macrophage subpopulations. The strain is often administered in microencapsulated forms to improve its survival during gastroduodenal transit and is frequently evaluated in combination with other probiotic strains such as *Lactobacillus acidophilus* LA02. Additionally, micronized cells (MCs) derived from this strain have been studied for their ability to mitigate oxidative stress and activate specific monocyte defense programs.
- Other names
- Bifidobacterium animalis subsp. lactis BS01B. lactis BS01
Beyond the preview
Go deeper on Bifidobacterium lactis BS01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium lactis BS01.